- Home
- TPG vs ROIV Comparison
TPG vs ROIV Comparison
Compare TPG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- ROIV
- Stock Information
- Founded
- TPG 1992
- ROIV 2014
- Country
- TPG United States
- ROIV United Kingdom
- Employees
- TPG N/A
- ROIV N/A
- Industry
- TPG Investment Managers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- ROIV Health Care
- Exchange
- TPG Nasdaq
- ROIV Nasdaq
- Market Cap
- TPG 9.1B
- ROIV 8.6B
- IPO Year
- TPG 2022
- ROIV N/A
- Fundamental
- Price
- TPG $58.51
- ROIV $16.17
- Analyst Decision
- TPG Buy
- ROIV Strong Buy
- Analyst Count
- TPG 14
- ROIV 8
- Target Price
- TPG $64.31
- ROIV $19.94
- AVG Volume (30 Days)
- TPG 1.5M
- ROIV 9.5M
- Earning Date
- TPG 11-03-2025
- ROIV 11-11-2025
- Dividend Yield
- TPG 2.97%
- ROIV N/A
- EPS Growth
- TPG N/A
- ROIV N/A
- EPS
- TPG N/A
- ROIV N/A
- Revenue
- TPG $3,887,230,000.00
- ROIV $23,233,000.00
- Revenue This Year
- TPG N/A
- ROIV N/A
- Revenue Next Year
- TPG $25.13
- ROIV $248.22
- P/E Ratio
- TPG $1,094.08
- ROIV N/A
- Revenue Growth
- TPG 43.35
- ROIV N/A
- 52 Week Low
- TPG $37.52
- ROIV $8.73
- 52 Week High
- TPG $72.98
- ROIV $16.19
- Technical
- Relative Strength Index (RSI)
- TPG 44.82
- ROIV 80.34
- Support Level
- TPG $55.38
- ROIV $14.86
- Resistance Level
- TPG $65.52
- ROIV $16.15
- Average True Range (ATR)
- TPG 1.85
- ROIV 0.43
- MACD
- TPG -0.63
- ROIV 0.06
- Stochastic Oscillator
- TPG 30.87
- ROIV 99.12
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.